InvestBio completes $20 million investment in Vaccine Co.

By Elaine Rigoli

Tampa, Fla., May 5 - InvestBio Ventures - The Vaccine Co. LP, an InvestBio Ventures Partnership, announced Friday that it has completed a $20 million investment in The Vaccine Co.

InvestPrivate, Inc. acted as the placement agent for the offering.

The Vaccine Co. was formed in July 2003 to commercialize the PR1 vaccine that is being developed at the M. D. Anderson Cancer Center at The University of Texas, according to a news release.

The funding will help The Vaccine Co. conduct a pivotal phase 3 trial in acute myelogenous leukemia.

New York-based InvestBio serves as a central resource for biotech investors seeking unbiased information and access to investment opportunities.

New York-based InvestPrivate is a boutique investment-brokerage firm that specializes in the biotechnology sector.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.